Shaanxi Meibang Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
Shaanxi Meibang Pharmaceutical Group Co Ltd cash flow-to-debt ratio. Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Cash Flow-to-Debt Ratio of 0.37x as of September 2025, meaning its operating cash flow of CN¥281.88 Million could theoretically repay 0% of its total liabilities (CN¥757.69 Million) in one year. Check 605033 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
Cash flow-to-debt ratio of Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024. Historical debt coverage capacity for Shaanxi Meibang Pharmaceutical Group Co Ltd across 8 annual periods. Check Shaanxi Meibang Pharmaceutical Group Co cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shaanxi Meibang Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (2017–2024)
Shaanxi Meibang Pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Shaanxi Meibang Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see 605033 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.38x | CN¥280.40 Million | CN¥737.37 Million | ▼ -34.4% |
| 2023 | 0.58x | CN¥334.79 Million | CN¥577.84 Million | ▲ +117.3% |
| 2022 | 0.27x | CN¥126.41 Million | CN¥474.14 Million | ▲ +221.7% |
| 2021 | -0.22x | CN¥-108.75 Million | CN¥496.43 Million | ▼ -198.5% |
| 2020 | 0.22x | CN¥74.88 Million | CN¥336.50 Million | ▼ -48.8% |
| 2019 | 0.43x | CN¥128.45 Million | CN¥295.34 Million | ▲ +693.5% |
| 2018 | 0.05x | CN¥16.96 Million | CN¥309.40 Million | ▼ -38.6% |
| 2017 | 0.09x | CN¥29.41 Million | CN¥329.23 Million | — |